Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Conditions
Brief summary
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.
Interventions
DRUGsaline infusion
saline infused at 30ml/hour
DRUGGLP-1-9,36 infusion
infused @ 1.2pmol/kg/min
DRUGExendin-9,39 at low dose
infused at 30pmol/kg/min
DRUGExendin-9,39 at high dose
infused @ 300pmol/kg/min
Sponsors
Adrian Vella
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy Not on any medication other than thyroid hormone replacement or OCP No history of diabetes No prior upper GI surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin Secretion | over 360 minutes of study |
Secondary
| Measure | Time frame |
|---|---|
| glucagon secretion | over 360 minutes of study |
Countries
United States
Outcome results
None listed